Literature DB >> 30338844

The Polish adaptation of the CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR).

Katarzyna Małaczynska-Rajpold1, Anna Smukowska-Gorynia2, Alice Heaney3, Stephen P McKenna3,4, Magdalena Janus2, Aleksander Araszkiewicz2, Stanislaw Jankiewicz2, Sylwia Slawek-Szmyt2, Iga Tomaszewska2, Tatiana Mularek-Kubzdela2.   

Abstract

BACKGROUND: Pulmonary hypertension (PH) results in severely impaired quality of life (QoL) in people with this condition. The CAMbridge Pulmonary Hypertension Outcome Review (CAMPHOR) is the only questionnaire providing a disease-specific measurement of symptoms, functioning and QoL in PH patients. It has already been adapted for use in several countries. The aim of this study was to adapt and validate CAMPHOR for the Polish-speaking population.
METHODS: Two panels (bilingual and lay) were conducted to translate CAMPHOR into Polish. This new version was then tested by cognitive debriefing interviews with 15 patients. Finally, a postal validation survey was conducted with 56 patients on two occasions 2 weeks apart to assess its psychometric properties.
RESULTS: No problems were experienced in producing a Polish translation of CAMPHOR. Interviewees responded well to the Polish CAMPHOR, finding it relevant, comprehensible and easy to complete. For all three CAMPHOR scales (Symptoms, Activity, QoL), The Cronbach alpha coefficients were above 0.8 at both time points, indicating high internal consistency. Test-retest reliability for the three scales achieved a value above 0.80. Predicted correlations with the Nottingham Health Profile provided evidence of the construct validity of CAMPHOR scales. The Polish CAMPHOR could distinguish between patients who differed according to their perceived general health and perceived disease severity. No significant differences in scores were found between participants grouped by gender or age.
CONCLUSIONS: The Polish version of CAMPHOR demonstrated good psychometric properties and is recommended for use in clinical practice.

Entities:  

Keywords:  CAMPHOR; adaptation; patient reported outcome; pulmonary hypertension; quality of life

Year:  2018        PMID: 30338844      PMCID: PMC8078996          DOI: 10.5603/CJ.a2018.0119

Source DB:  PubMed          Journal:  Cardiol J        ISSN: 1898-018X            Impact factor:   2.737


  30 in total

1.  Comparison of cardiac and pulmonary-specific quality-of-life measures in pulmonary arterial hypertension.

Authors:  H Chen; T De Marco; E A Kobashigawa; P P Katz; V W Chang; P D Blanc
Journal:  Eur Respir J       Date:  2011-01-27       Impact factor: 16.671

2.  Defining patient-reported outcomes.

Authors:  Lynda C Doward; Stephen P McKenna
Journal:  Value Health       Date:  2004 Sep-Oct       Impact factor: 5.725

3.  The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension.

Authors:  S P McKenna; N Doughty; D M Meads; L C Doward; J Pepke-Zaba
Journal:  Qual Life Res       Date:  2006-02       Impact factor: 4.147

Review 4.  End points and clinical trial design in pulmonary arterial hypertension.

Authors:  Vallerie V McLaughlin; David B Badesch; Marion Delcroix; Thomas R Fleming; Sean P Gaine; Nazzareno Galiè; J Simon R Gibbs; Nick H Kim; Ronald J Oudiz; Andrew Peacock; Steeve Provencher; Olivier Sitbon; Victor F Tapson; Werner Seeger
Journal:  J Am Coll Cardiol       Date:  2009-06-30       Impact factor: 24.094

5.  Measuring health status: a new tool for clinicians and epidemiologists.

Authors:  S M Hunt; J McEwen; S P McKenna
Journal:  J R Coll Gen Pract       Date:  1985-04

6.  The QLDS: a scale for the measurement of quality of life in depression.

Authors:  S M Hunt; S P McKenna
Journal:  Health Policy       Date:  1992-10       Impact factor: 2.980

7.  Symptom Prevalence, Symptom Severity, and Health-Related Quality of Life Among Young, Middle, and Older Adults With Pulmonary Arterial Hypertension.

Authors:  Lea Ann Matura; Annette McDonough; Diane L Carroll
Journal:  Am J Hosp Palliat Care       Date:  2014-10-07       Impact factor: 2.500

8.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

9.  Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire.

Authors:  Abílio Reis; James Twiss; Margarida Vicente; Fabienne Gonçalves; Luísa Carvalho; José Meireles; Alzira Melo; Stephen P McKenna; Luís Almeida
Journal:  Health Qual Life Outcomes       Date:  2016-07-26       Impact factor: 3.186

10.  Adaptation and validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Netherlands.

Authors:  M Wapenaar; J Twiss; M Wagenaar; P Seijkens; L van den Toorn; J Stepanous; A Heaney; A van den Bosch; K A Boomars
Journal:  Neth Heart J       Date:  2016-06       Impact factor: 2.380

View more
  1 in total

1.  A minimal clinically important difference measured by the Cambridge Pulmonary Hypertension Outcome Review for patients with idiopathic pulmonary arterial hypertension.

Authors:  Katherine Bunclark; Natalie Doughty; Alice Michael; Nisha Abraham; Samantha Ali; John E Cannon; Karen Sheares; Nicola Speed; Dolores Taboada; Mark Toshner; Joanna Pepke-Zaba
Journal:  Pulm Circ       Date:  2021-05-21       Impact factor: 3.017

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.